Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Rising global prevalence of obesity and type 2 diabetes is a primary growth driver for the market
Gastrointestinal adverse effects were not totaled but nausea, which is a common one, was less common than for the subQ drugs above
Besides improving glucose control, reducing body weight, and lowering arterial blood pressure (surrogate endpoints), the breakthroughs were the demonstration of a significant reduction in cardiovascular and renal events in patients with type 2 diabetes at high risk
Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop
:max_bytes(150000):strip_icc()/VWH-GettyImages-1469751146-5eff6dd0b38449ff9dca9313c7c393d5.jpg)
US$ 22.63
:max_bytes(150000):strip_icc()/VWH-GettyImages-2275860768-a6f6e63304e048d0a829844c1dacbd8d.jpg)
US$ 22.10
